Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Mediators Inflamm ; 2020: 1678780, 2020.
Article de Anglais | MEDLINE | ID: mdl-33488292

RÉSUMÉ

Persistent infection with high-risk human papillomavirus (HR-HPV) is the main factor in the development of cervical cancer (CC). The presence of immunosuppressive factors plays an important role in the development of this type of cancer. To determine whether CD39 and CD73, which participate in the production of immunosuppressive adenosine (Ado), are involved in the progression of CC, we compared the concentrations and hydrolytic activity of these ectonucleotidases in platelet-free plasma (PFP) samples between patients with low-grade squamous intraepithelial lesions (LSILs) (n = 18), high-grade squamous intraepithelial lesions (HSILs) (n = 12), and CC (n = 19) and normal donors (NDs) (n = 15). The concentrations of CD39 and CD73 in PFP increased with disease progression (r = 0.5929, p < 0.001). The PFP of patients with HSILs or CC showed the highest concentrations of CD39 (2.3 and 2.2 times that of the NDs, respectively) and CD73 (1.7 and 2.68 times that of the NDs, respectively), which were associated with a high capacity to generate Ado from the hydrolysis of adenosine diphosphate (ADP) and adenosine monophosphate (AMP). The addition of POM-1 and APCP, specific inhibitors of CD39 and CD73, respectively, inhibited the ADPase and AMPase activity of PFP by more than 90%. A high level of the 90 kD isoform of CD73 was detected in the PFP of patients with HSILs or CC. Digestion with endoglycosidase H and N-glycanase generated CD73 with weights of approximately 90 kD, 85 kD, 80 kD, and 70 kD. In addition, the levels of transforming grow factor-ß (TGF-ß) in the PFPs of patients with LSIL, HSIL and CC positively correlated with those of CD39 (r = 0.4432, p < 0.001) and CD73 (r = 0.5786, p < 0.001). These results suggest that persistent infection by HR-HPV and the concomitant production of TGF-ß promote the expression of CD39 and CD73 to favor CC progression through Ado generation.


Sujet(s)
5'-Nucleotidase/métabolisme , Antigènes CD/métabolisme , Apyrase/métabolisme , Tumeurs du col de l'utérus/métabolisme , ADP/métabolisme , AMP/métabolisme , Adulte , Test ELISA , Femelle , Humains
2.
Cytokine ; 118: 71-79, 2019 06.
Article de Anglais | MEDLINE | ID: mdl-30301599

RÉSUMÉ

In cancer, the adenosinergic pathway participates in the generation of an immunosuppressive microenvironment and in the promotion of tumor growth through the generation of adenosine (Ado). The present study analyzed the participation of Ado, generated through the functional activity of the cervical cancer (CeCa) pathway in CeCa cells, to induce the expression and secretion of TGF-ß1, as well as the participation of this factor to maintain CD73 expression. Ado concentrations greater than 10 µM were necessary to induce an increase of over 50% in the production and expression of TGF-ß1 in CeCa tumor cells. Blockade of A2AR and A2BR with the specific antagonists, ZM241385 and MRS1754, respectively, strongly reversed the production of TGF-ß1. TGF-ß1 produced by CeCa cells was necessary to maintain CD73 expression because the addition of anti-TGF-ß neutralizing antibodies or the inhibition of TGF-ßRI strongly reversed the expression of CD73 in the CeCa cells. These results suggested a feedback loop in CeCa cells that favors immunosuppressive activity through the production of TGF-ß1 and Ado as well as the autocrine activity of TGF-ß1 and expression of CD73.


Sujet(s)
5'-Nucleotidase/métabolisme , Adénosine/métabolisme , Communication autocrine/physiologie , Facteur de croissance transformant bêta-1/métabolisme , Tumeurs du col de l'utérus/métabolisme , Acétamides/pharmacologie , Antagonistes des récepteurs A2 à l'adénosine/pharmacologie , Lignée cellulaire tumorale , Femelle , Protéines liées au GPI/métabolisme , Cellules HeLa , Humains , Immunosuppression thérapeutique/méthodes , Purines/pharmacologie , Récepteur A2A à l'adénosine/métabolisme , Récepteur A2B à l'adénosine/métabolisme , Triazines/pharmacologie , Triazoles/pharmacologie , Microenvironnement tumoral/effets des médicaments et des substances chimiques , Tumeurs du col de l'utérus/traitement médicamenteux
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE